These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21507717)

  • 1. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
    Ogbomo H; Cinatl J; Mody CH; Forsyth PA
    Trends Mol Med; 2011 Aug; 17(8):433-41. PubMed ID: 21507717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous natural killer cell therapy for human recurrent malignant glioma.
    Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
    Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
    Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
    Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells and solid tumors.
    Stojanovic A; Cerwenka A
    J Innate Immun; 2011; 3(4):355-64. PubMed ID: 21502747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E; Takano S; Ohno T; Tsuboi K
    Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions.
    Ishikawa E; Tsuboi K; Saijo K; Takano S; Ohno T
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1505-12. PubMed ID: 15275738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of CNS malignancies.
    Plautz GE; Shu S
    Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cellular therapy with natural killer cells.
    Klingemann H; Boissel L
    Horm Metab Res; 2008 Feb; 40(2):122-5. PubMed ID: 18283630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic activity of NK cells against tumors.
    Basse PH; Whiteside TL; Chambers W; Herberman RB
    Int Rev Immunol; 2001 Jun; 20(3-4):439-501. PubMed ID: 11878512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
    Terme M; Ullrich E; Delahaye NF; Chaput N; Zitvogel L
    Nat Immunol; 2008 May; 9(5):486-94. PubMed ID: 18425105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human natural killer cells: a comprehensive review.
    Sinkovics JG; Horvath JC
    Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
    Yamasaki T
    Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunobiology of natural killer cells and bone marrow allograft rejection.
    Barao I; Murphy WJ
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):727-41. PubMed ID: 14677112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1.
    Roth P; Mittelbronn M; Wick W; Meyermann R; Tatagiba M; Weller M
    Cancer Res; 2007 Apr; 67(8):3540-4. PubMed ID: 17440061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
    Janelidze S; Bexell D; Badn W; Darabi A; Smith KE; Fritzell S; Gunnarsson S; Milos P; Bengzon J; Salford LG; Siesjö P; Visse E
    J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of human natural killer cells.
    Whiteside TL; Herberman RB
    Ann Ist Super Sanita; 1990; 26(3-4):335-48. PubMed ID: 2091502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.